Clinical Trial Update: Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating sintilimab in combination with carboplatin and nab-paclitaxel for resectable oral cavity and oropharyngeal squamous cell ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING